keyword
MENU ▼
Read by QxMD icon Read
search

souhami

keyword
https://www.readbyqxmd.com/read/27780694/stereotactic-ablative-radiotherapy-versus-low-dose-rate-brachytherapy-or-external-beam-radiotherapy-propensity-score-matched-analyses-of-canadian-data
#1
A Loblaw, T Pickles, J Crook, A-G Martin, E Vigneault, L Souhami, F Cury, J Morris, C Catton, H Lukka, P Cheung, P Sethukavalan, A Warner, Y Yang, G Rodrigues
AIMS: To compare biochemical failure-free survival (BFFS) and overall survival for prostate cancer treated with stereotactic ablative radiotherapy (SABR), low dose rate (LDR) brachytherapy or external beam radiotherapy (EBRT) using a large Canadian multi-institutional database. MATERIALS AND METHODS: Patients with low risk localised prostate cancer treated with SABR, LDR or EBRT and no androgen deprivation therapy were selected. Propensity score matching was used to create two sets of matched cohorts with LDR and EBRT serving as control groups...
October 22, 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/27675942/updated-4-year-results-for-nrg-oncology-rtog-0921-a-phase-2-study-of-postoperative-intensity-modulated-radiation-therapy-with-concurrent-cisplatin-and-bevacizumab-followed-by-carboplatin-and-paclitaxel-for-patients-with-endometrial-cancer
#2
A N Viswanathan, K Winter, B E Miller, Y Xiao, A Jhingran, L Portelance, W R Bosch, U Matulonis, N Horowitz, R Mannel, L Souhami, B A Erickson, W Small, D K Gaffney
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27675736/second-malignancies-as-first-cause-of-death-in-localized-prostate-cancer-treated-with-radiation-therapy-data-from-two-phase-3-trials
#3
A Nabid, N Carrier, E Vigneault, L Souhami, C Lemaire, M A Brassard, B Bahoric, R Archambault, F Vincent, T V Nguyen
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27675716/funding-source-self-reported-conflicts-of-interest-and-the-interpretation-of-conclusions-of-phase-1-2-and-3-trials-in-neuro-oncology
#4
F Y Moraes, L C Mendez, J H Suh, N K Taunk, L Souhami, B J Slotman, E Weltman, G N Marta
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27675463/analysis-of-prognostic-factors-for-local-recurrence-in-atypical-meningiomas
#5
S I Shakir, L Souhami, K Petrecca, J J Mansure, S Khushdeep, V Panet-Raymond, G Shenouda, A Al Odaini, B S Abdulkarim, M C Guiot
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27674349/outcomes-of-adjuvant-therapy-in-stage-3-endometrial-cancer-confined-to-the-pelvis
#6
R M Albeesh, J Alfieri, J J Mansure, G A Turgeon, L Fu, J Arseneau, K Jardon, L Gilbert, L Souhami
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27673821/trial-sponsorship-and-self-reported-conflicts-of-interest-in-clinical-trials-of-central-nervous-system-malignancies
#7
L C Mendez, F Y Moraes, J H Suh, N K Taunk, L Souhami, B J Slotman, E Weltman, G N Marta
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27650977/efficacy-and-safety-of-lixilan-a-titratable-fixed-ratio-combination-of-insulin-glargine-plus-lixisenatide-in-type-2-diabetes-inadequately-controlled-on-basal-insulin-and-metformin-the-lixilan-l-randomized-trial
#8
Vanita R Aroda, Julio Rosenstock, Carol Wysham, Jeffrey Unger, Diego Bellido, Guillermo González-Gálvez, Akane Takami, Hailing Guo, Elisabeth Niemoeller, Elisabeth Souhami, Richard M Bergenstal
OBJECTIVE: This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents. RESEARCH DESIGN AND METHODS: After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/m(2)) were randomized 1:1 to open-label, once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose <100 mg/dL (<5...
November 2016: Diabetes Care
https://www.readbyqxmd.com/read/27527848/benefits-of-lixilan-a-titratable-fixed-ratio-combination-of-insulin-glargine-plus-lixisenatide-versus-insulin-glargine-and-lixisenatide-monocomponents-in-type-2-diabetes-inadequately-controlled-on-oral-agents-the-lixilan-o-randomized-trial
#9
Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti, Pierre Serusclat, Xi Cheng, Tianyue Zhou, Elisabeth Niemoeller, Elisabeth Souhami, Melanie Davies
OBJECTIVE: To evaluate efficacy and safety of LixiLan (iGlarLixi), a novel titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both components, iGlar and Lixi, given separately in type 2 diabetes inadequately controlled on metformin with or without a second oral glucose-lowering drug. RESEARCH DESIGN AND METHODS: After a 4-week run-in to optimize metformin and stop other oral antidiabetic drugs, participants (N = 1,170, mean diabetes duration ∼8...
November 2016: Diabetes Care
https://www.readbyqxmd.com/read/27379211/big-data-analytics-for-prostate-radiotherapy
#10
REVIEW
James Coates, Luis Souhami, Issam El Naqa
Radiation therapy is a first-line treatment option for localized prostate cancer and radiation-induced normal tissue damage are often the main limiting factor for modern radiotherapy regimens. Conversely, under-dosing of target volumes in an attempt to spare adjacent healthy tissues limits the likelihood of achieving local, long-term control. Thus, the ability to generate personalized data-driven risk profiles for radiotherapy outcomes would provide valuable prognostic information to help guide both clinicians and patients alike...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27284114/efficacy-and-safety-of-lixilan-a-titratable-fixed-ratio-combination-of-lixisenatide-and-insulin-glargine-versus-insulin-glargine-in-type-2-diabetes-inadequately-controlled-on-metformin-monotherapy-the-lixilan-proof-of-concept-randomized-trial
#11
Julio Rosenstock, Michaela Diamant, Vanita R Aroda, Louise Silvestre, Elisabeth Souhami, Tianyue Zhou, Riccardo Perfetti, Vivian Fonseca
OBJECTIVE: This study assessed the efficacy and safety of LixiLan, a fixed-ratio, titratable, combination of 2 units insulin glargine (Gla-100) and 1 μg lixisenatide administered once daily via a single pen, versus Gla-100 in insulin-naïve type 2 diabetes on metformin. RESEARCH DESIGN AND METHODS: Participants were randomized to once-daily LixiLan (n = 161) or Gla-100 (n = 162) for 24 weeks, while continuing metformin. LixiLan and Gla-100 were started at 10 units/5 μg and 10 units, respectively, and titrated based on the Gla-100 requirement according to fasting plasma glucose levels...
September 2016: Diabetes Care
https://www.readbyqxmd.com/read/27222510/prandial-options-to-advance-basal-insulin-glargine-therapy-testing-lixisenatide-plus-basal-insulin-versus-insulin-glulisine-either-as-basal-plus-or-basal-bolus-in-type-2-diabetes-the-getgoal-duo-2-trial
#12
Julio Rosenstock, Bruno Guerci, Markolf Hanefeld, Sandro Gentile, Ronnie Aronson, Francisco J Tinahones, Christine Roy-Duval, Elisabeth Souhami, Marek Wardecki, Jenny Ye, Riccardo Perfetti, Simon Heller
OBJECTIVE: To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1-3 oral antidiabetic agents (OADs). RESEARCH DESIGN AND METHODS: Patients were randomized to lixisenatide once daily or insulin glulisine given once or thrice daily, added to glargine, with or without metformin, if HbA1c remained ≥7 to ≤9% (≥53 to ≤75 mmol/mol) after 12 weeks of glargine optimization with OADs other than metformin stopped at the start of optimization...
August 2016: Diabetes Care
https://www.readbyqxmd.com/read/27217852/enumerating-pelvic-recurrence-following-radical-cystectomy-for-bladder-cancer-a-canadian-multi-institutional-study
#13
Libni J Eapen, Edward Jones, Wassim Kassouf, Carole Lambert, Scott C Morgan, Madeleine Moussa, Robert Nam, Matthew Parliament, Laurie Russell, Fred Saad, D Robert Siemens, Luis Souhami, Ewa Szumacher, Scott Tyldesley, Yan Xu, Ingrid Zbieranowski, Rodney H Breau, Eric Belanger, Peter Black, Eric Estey, Julie Bowan, Bishwajit Bora, Michael Brundage, Peter Chung, Neil Fleshner, Andrew Evans, Glenn Bauman, Jonathan Izawa, Chris Davidson, Fadi Brimo
INTRODUCTION: We aimed to enumerate the rate of pelvic recurrence following radical cystectomy at university-affiliated hospitals in Canada. METHODS: Canadian, university-affiliated hospitals were invited to participate. They were asked to identify the first 10 consecutive patients undergoing radical cystectomy starting January 1, 2005, who had urothelial carcinoma stages pT3/T4 N0-2 M0. The first 10 consecutive cases starting January 1, 2005 who met these criteria were the patients submitted by that institution with information regarding tumour stage, age, number of nodes removed, and last known clinical status in regard to recurrence and patterns of failure...
March 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27085825/moderate-hypofractionated-external-beam-radiotherapy-alone-for-intermediate-risk-prostate-cancer-long-term-outcomes
#14
Sergio L Faria, Osmar B Neto, Fabio Cury, George Shenouda, Ruo Russel, Luis Souhami
INTRODUCTION: To report long term toxicity and efficacy of patients with intermediate risk prostate cancer treated with moderate hypofractionated radiotherapy (HypoRT). MATERIALS AND METHODS: We studied the first consecutive 100 men with intermediate risk (stage T2b-T2c, or PSA = 10-20 ug/L, or Gleason score = 7) adenocarcinoma of the prostate treated between October 2002 and May 2010 in our institution with moderate HypoRT. Patients were treated using three-dimensional conformal HypoRT to a dose of 66 Gy in 22 daily fractions prescribed to the isocenter...
April 2016: Canadian Journal of Urology
https://www.readbyqxmd.com/read/27056435/prostate-cancer-radiation-therapy-a-physician-s-perspective
#15
REVIEW
Alan Dal Pra, Luis Souhami
Prostate cancer is the second most common cancer in men and a major cause of cancer deaths worldwide. Ionizing radiation has played a substantial role in the curative treatment of this disease. The historical evolution of radiotherapy techniques through 3D-conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), and image-guided radiotherapy (IGRT) has allowed more accurate and precise treatments toward significant improvements in the therapeutic ratio. The addition of androgen deprivation therapy has significantly improved overall survival becoming the standard therapy for intermediate- and high-risk disease...
March 2016: Physica Medica: PM
https://www.readbyqxmd.com/read/26700703/long-term-outcomes-among-patients-who-achieve-complete-or-near-complete-responses-after-the-induction-phase-of-bladder-preserving-combined-modality-therapy-for-muscle-invasive-bladder-cancer-a-pooled-analysis-of-nrg-oncology-rtog-9906-and-0233
#16
RANDOMIZED CONTROLLED TRIAL
Timur Mitin, Asha George, Anthony L Zietman, Niall M Heney, Donald S Kaufman, Robert G Uzzo, Robert Dreicer, H James Wallace, Luis Souhami, M Chris Dobelbower, Howard M Sandler, William U Shipley
PURPOSE: To investigate the differences in outcomes among patients with muscle-invasive bladder cancer on NRG Oncology Radiation Therapy Oncology Group protocols 9906 and 0233 who achieved complete response and near-complete response after induction chemoradiation and then completed bladder-preserving therapy with chemoradiation therapy (chemo-RT) to full dose (60-64 Gy). PATIENTS AND METHODS: A pooled analysis was performed on 119 eligible patients with muscle-invasive bladder cancer enrolled on NRG Oncology Radiation Therapy Oncology Group trials 9906 and 0233, who were classified as having a complete (T0) or near-complete (Ta or Tis) response after induction chemo-RT and completed consolidation with a total RT dose of at least 60 Gy...
January 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/26362090/cardiovascular-mortality-following-short-term-androgen-deprivation-in-clinically-localized-prostate-cancer-an-analysis-of-rtog-94-08
#17
RANDOMIZED CONTROLLED TRIAL
Justin C Voog, Rebecca Paulus, William U Shipley, Matthew R Smith, David G McGowan, Christopher U Jones, Jean-Paul Bahary, Kenneth L Zeitzer, Luis Souhami, Mark H Leibenhaut, Marvin Rotman, Siraj M Husain, Elizabeth Gore, Adam Raben, Susan Chafe, Howard M Sandler, Jason A Efstathiou
BACKGROUND: Androgen deprivation therapy (ADT) is associated with coronary heart disease and diabetes in men with prostate cancer (PCa); however, controversy exists regarding ADT and cardiovascular mortality (CVM) with limited data for lower risk disease. OBJECTIVE: We conducted a hypothesis-generating retrospective analysis to evaluate the relationship between short-course ADT and CVM in patients with clinically localized PCa enrolled in a phase III trial. DESIGN, SETTING, AND PARTICIPANTS: A total of 1979 men with clinically localized (T1b-2b, prostate-specific antigen [PSA] <20 ng/ml) PCa enrolled in Radiation Therapy Oncology Group (RTOG) 94-08 from 1994 to 2001...
February 2016: European Urology
https://www.readbyqxmd.com/read/26278988/hypofractionated-radiation-therapy-for-prostate-cancer-the-mcgill-university-health-center-experience
#18
O Barbosa Neto, L Souhami, S Faria
PURPOSE: In 2002, at the McGill University Health Centre, we began a program of hypofractionated radiotherapy for patients with low risk prostate cancer as an alternative to conventionally fractionated radiotherapy. MATERIAL AND METHODS: Our initial hypofractionation regimen was 66 Gy given in 22 fractions, prescribed to the isocenter, delivered with 3D-conformal radiotherapy plan. The clinical target volume was the prostate gland and the planning target volume consisted of the clinical target volume plus a 7-mm margin in all directions...
October 2015: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/26180700/development-of-procars-clinical-nomograms-for-biochemical-failure-free-survival-following-either-low-dose-rate-brachytherapy-or-conventionally-fractionated-external-beam-radiation-therapy-for-localized-prostate-cancer
#19
Andrew Warner, Tom Pickles, Juanita Crook, Andre-Guy Martin, Luis Souhami, Charles Catton, Himu Lukka, George Rodrigues
PURPOSE: Although several clinical nomograms predictive of biochemical failure-free survival (BFFS) for localized prostate cancer exist in the medical literature, making valid comparisons can be challenging due to variable definitions of biochemical failure, the disparate distribution of prognostic factors, and received treatments in patient populations. The aim of this investigation was to develop and validate clinically-based nomograms for 5-year BFFS using the ASTRO II "Phoenix" definition for two patient cohorts receiving low-dose rate (LDR) brachytherapy or conventionally fractionated external beam radiation therapy (EBRT) from a large Canadian multi-institutional database...
June 2015: Curēus
https://www.readbyqxmd.com/read/26127006/pelvic-lymph-node-displacement-in-high-risk-prostate-cancer-patients-treated-with-image-guided-intensity-modulated-radiation-therapy-with-2-independent-target-volumes
#20
Magali Lecavalier-Barsoum, Luis Souhami, Fabio Cury, Marie Duclos, Russel Ruo, Sergio Faria
PURPOSE: To evaluate the displacement of the pelvic lymph node (PLN) target when using cone beam computed tomography (CBCT) for localization of the prostate in patients treated with simultaneous integrated boost. METHODS AND MATERIALS: High-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with simultaneous integrated boost receiving 60 Gy in 20 fractions to the prostate and proximal seminal vesicles (PTV60) and 44 Gy in the same 20 fractions to the PLN (PTV44) were studied...
November 2015: Practical Radiation Oncology
keyword
keyword
14147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"